Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, resulting in a Form 483 with six observations. The company confirmed that these relate to procedural improvements, not data integrity. Additionally, Piramal reported a 13% YoY revenue growth in Q3FY25, with a strong target price outlook.
